Page 195 - PRECONGRESS COURSE 06

S
S
t
ti
i
m
m
u
u
l
l
a
a
t
t
i
io
o
n
n
o
of
fc
co
or
rp
p
o
o
r
ra
a
l
l
u
ut
te
ea
a
a
af
ft
te
er
rG
G
n
n
R
RH
Ha
ag
g
o
o
n
ni
i
s
s
t
tt
t
r
ri
i
g
g
g
g
e
er
ri
in
n
g
g
S
ta
St
t
i
i
m
m
u
u
l
la
a
t
ti
io
on
n
o
of
fe
e
n
n
d
d
o
og
ge
en
n
o
ou
u
s
sL
L
H
Hl
d
n
d
u
u
le
ev
r
ri
v
e
in
n
e
l
g
g
t
l
s
sw
t
h
wi
he
e
l
it
t
h
hr
lu
u
t
re
te
e
ea
a
p
p
l
l
p
e
e
p
a
at
h
te
ha
e
as
d
d
G
se
e
G
n
n
R
R
H
H
a
a
g
g
o
on
ni
is
s
t
a
d
dm
mi
in
n
i
is
st
tr
r
a
a
t
t
i
i
o
o
n
S
ta
St
t
i
i
m
m
u
u
l
la
a
t
ti
io
on
n
o
of
fe
e
n
n
d
d
o
og
ge
en
n
o
ou
u
s
sL
L
H
Hl
d
n
d
u
u
le
ev
r
ri
v
e
in
n
e
l
g
g
t
l
s
sw
t
h
wi
he
e
l
it
t
h
hr
lu
u
t
re
te
e
ea
a
p
p
l
l
p
e
e
p
a
at
h
te
ha
e
as
d
d
G
se
e
G
n
n
R
R
H
H
a
a
g
g
o
on
ni
is
s
t
a
d
dm
mi
in
n
i
is
st
tr
r
a
a
t
t
i
i
o
o
n
Single small RCT In low risk patients
Agonist triggering
hCG triggering
N=5
N=5
Luteal phase support
100 μg IN buserelin three times a day for 15 days
Vag P
Delivery rate
40 11.8 – 76.9
20 3.6 – 62.5
Severe OHSS
0
0- 43.5
0
0 – 43.5
Pirard et al 2006
Page 191 of 258
PRECONGRESS COURSE 06 I GENEVA, SWITZERLAND – 2 JULY 2017 195